This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Exchange: OTC BB
Recent Price: $.15
Market Cap: $8.2M
52 Week Range: $.05- $5.50
Shares Outstanding: 53.7 M
Approximate Float: 14 M
Reach the unmet needs of the Infertility population through providing
used. Using a mild stimulation protocol, 1-10 oocytes are retrieved under light
3 days. After 3 days, the patient returns to the physician’s office where the
INVOcell is removed.
inner vessel is placed in INVO Bioscience’s patented Holding Block in a vertical
position for 15 minutes. The embryos can be directly viewed from the micro chamber
in the holding block by using a microscope.
Illustration of the INVO procedure
Similar efficacy to IVF
Lower cost to achieve pregnancy
Greater geographic availability
Greater patient involvement
Europe Based on efficacy rates/cycles/cost
American INVO Center had officially opened in Cali, Colombia, and six existing In-Vitro Fertilization (IVF) centers located in Armenia, Cúcuta, Bogotá, Ibagué, Medellin and Ubate, Colombia are also now offering the INVO procedure
The INVOcell and INVO process is a multi billion dollar business if INVO Bioscience penetrates 5% of the unmet need.
The INVOcell device was specially developed and manufactured
to optimize the ease of use and effectiveness of the procedure
at an affordable price. This product development process has
resulted in 5 active patents world wide covering the
INVOcell device, the INVO process and the Holding Block.
transactions to expand the rate of launch throughout the world and bring INVO Bioscience to break even position.
. Dr. Suheil Jamil Muasher: Dr. Muasher has been Medical Director of the Jones Institute from 2001 to 2004. He is the Medical Director of The Muasher Center for Fertility and IVF. Dr. Muasher is Clinical Professor of the Department of Obstetrics and Gynecology at George Washington University, Associate Professor of Department of Gynecology and Obstetrics at Johns Hopkins University School of Medicine and Professor of the Department of Obstetrics and Gynecology at Virginia Commonwealth University.
INVO Bioscience’s INVOcell and INVO technology will revolutionize the Infertility world by expanding fertility treatment to millions of couples who are suffering from infertility by providing:
Kathleen Karloff - CEO
INVO Bioscience Inc.
Tony Schor – President
Investor Awareness, Inc.